Image by Wyman Meinzer

Pipeline

Reata's technologies and development programs have yielded a deep pipeline of preclinical- and clinical-stage drug candidates for a broad array of indications where there is significant unmet need.

READ MORE »

News

09.30.2014 -  Reata Announces the Initiation of Phase 2 Studies Examining RTA 408 for the Treatment of Friedreich's Ataxia and Mitochondrial Myopathies

07.25.2014Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis

06.02.2014 Reata Pharmaceuticals Announces Late-Breaking Presentation at European Renal Association - European Dialysis and Transplant Association Congress 

READ MORE »

In-licensing

Reata is actively seeking in-licensing and collaborative development opportunities for novel therapeutics to supplement our internal discovery efforts.

READ MORE »